Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) went up by 4.18% from its latest closing price compared to the recent 1-year high of $92.60. The company’s stock price has collected 15.44% of gains in the last five trading sessions. Press Release reported on 06/03/21 that Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Is It Worth Investing in Arrowhead Pharmaceuticals Inc. (NASDAQ :ARWR) Right Now?
Plus, the 36-month beta value for ARWR is at 1.26. Opinions of the stock are interesting as 9 analysts out of 12 who provided ratings for Arrowhead Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $88.67, which is $3.53 above the current price. ARWR currently public float of 100.35M and currently shorts hold a 4.80% ratio of that float. Today, the average trading volume of ARWR was 713.92K shares.
ARWR’s Market Performance
ARWR stocks went up by 15.44% for the week, with a monthly jump of 19.93% and a quarterly performance of 14.40%, while its annual performance rate touched 139.13%. The volatility ratio for the week stands at 4.59% while the volatility levels for the past 30 days are set at 3.95% for Arrowhead Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 16.75% for ARWR stocks with a simple moving average of 30.61% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Robert W. Baird repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Robert W. Baird is $85 based on the research report published on June 04th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $95, previously predicting the price at $90. The rating they have provided for ARWR stocks is “Buy” according to the report published on February 05th, 2021.
Robert W. Baird gave a rating of “Neutral” to ARWR, setting the target price at $75 in the report published on December 21st of the previous year.
ARWR Trading at 23.24% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.81% of loss for the given period.
Volatility was left at 3.95%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares surge +28.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.81% upper at present.
During the last 5 trading sessions, ARWR rose by +14.80%, which changed the moving average for the period of 200-days by +101.72% in comparison to the 20-day moving average, which settled at $75.68. In addition, Arrowhead Pharmaceuticals Inc. saw 9.11% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ARWR starting from GIVEN DOUGLAS B, who sale 1,125 shares at the price of $88.73 back on Feb 22. After this action, GIVEN DOUGLAS B now owns 13,875 shares of Arrowhead Pharmaceuticals Inc., valued at $99,821 using the latest closing price.
O’Brien Patrick, the General Counsel of Arrowhead Pharmaceuticals Inc., sale 90,000 shares at $88.46 during a trade that took place back on Feb 08, which means that O’Brien Patrick is holding 293,375 shares at $7,961,240 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -105.87 for the present operating margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -96.09. The total capital return value is set at -25.63, while invested capital returns managed to touch -23.28. Equity return is now at value -23.60, with -18.80 for asset returns.
Based on Arrowhead Pharmaceuticals Inc. (ARWR), the company’s capital structure generated 4.58 points at debt to equity in total, while total debt to capital is 4.38. Total debt to assets is 4.05, with long-term debt to equity ratio resting at 4.34. Finally, the long-term debt to capital ratio is 4.15.
When we switch over and look at the enterprise to sales, we see a ratio of 45.94, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 116.78 and the total asset turnover is 0.20. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.92.